The bempedoic acid in clinical practice
DOI:
https://doi.org/10.34687/2219-8202.JAD.2024.03.0002Keywords:
bempedoic acid, lipid-lowering therapy, atherosclerosis, target LDL cholesterol levelAbstract
This literature review provides information about a new and currently not registered oral lipid-lowering drug in the Russian Federation - Bempedoic acid. This review article presents data on the mechanism of action, efficacy and safety, the effect on the risk of developing diabetes mellitus, and describes the results of basic clinical studies. The data are presented that the use of bempedoic acid, both in combination with other lipid-lowering drugs and as monotherapy, will take its place as a secondary and primary prevention of atherosclerosis and associated diseases.
Downloads
References
Chubykina UV, Ezhov MV, Rozhkova TA, Tamaeva BM, Sokolov AA, Ershova AI, et al. A five-year follow-up period
in homoand heterozygous familial hypercholesterolemia patients of the RENAISSANCE registry. Atherosclerosis and
dyslipidemia. 2023;1(50):5-18. In Russian. (Чубыкина У.В., Ежов М.В., Рожкова Т.А., Тамаева Б.М., Соколов А.А., Ер-
шова А.И. и др. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхо-
лестеринемией в регистре РЕНЕССАНС. Атеросклероз и дислипидемии. 2023;1(50):5-18). doi: 10.34687/2219-8202.
JAD.2023.01.0001.
Sergienko IV, Zubareva MYu, Gornyakova NB, Ansheles AA, Drapkina OM, Shepel RN, et al. Efficacy, safety and tolerability
of long-term therapy with rosuvastatin and its fixed combination with lisinopril and amlodipine in patients with high
and very high cardiovascular risk according to an observational study of ANICHKOV. Atherosclerosis and dyslipidemia.
;2(35):22-32. In Russian. (Сергиенко И.В., Зубарева М.Ю., Горнякова Н.Б., Аншелес А.А., Драпкина О.М., Шепель Р.Н.
и др. Эффективность, безопасность и переносимость длительной терапии розувастатином и его фиксированной
комбинации с лизиноприлом и амлодипином у больных высокого и очень высокого сердечно-сосудистого риска по
результатам наблюдательного исследования АНИЧКОВ. Атеросклероз и дислипидемии. 2019;2(35):22-32).
Sergienko IV, Ezhov MV, Gurevich VS, Zafiraki VK, Barov PA, Tsygankova OV, et al. Comparative efficacy and safety
of statins monotherapy and their combination with ezetimibe Results of the Russian retrospective observational study
UNISON. Atherosclerosis and dyslipidemia. 2022;4(49):25-38. In Russian. (Сергиенко И.В., Ежов М.В., Гуревич В.С., За-
фираки В.К., Баров П.А., Цыганкова О.В. и др. Сравнительная эффективность и безопасность монотерапии стати-
нами и их комбинации с эзетимибом. Результаты российского ретроспективного наблюдательного исследования
УНИСОН. Атеросклероз и дислипидемии. 2022;4(49):25-38). doi: 10.34687/2219-8202.JAD.2022.04.0003.
Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, et al. Bempedoic acid and
its role in contemporary management of hyperlipidemia in atherosclerosis. Ann Med. 2022;54(1):1287-1296. doi:
1080/07853890.2022.2059559.
Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscl
Rep. 2016;18(10):61. doi: 10.1007/s11883-016-0611-4.
Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by
bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communic. 2016;7:13457. doi: 10.1038/ncomms13457.
Cicero AF, Fogacci F, Cincione I. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
Exp Opin Drug Metabol Toxicol. 2021;17(9):1031-1038. doi: 10.1080/17425255.2021.1951222.
Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatol. 2013;57(3):873-
doi: 10.1002/hep.26175.
Chandramahanti S, Farzam K. Bempedoic Acid. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2023.
Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, et al. Efficacy and safety of bempedoic acid for prevention
of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):128. doi:
1186/s12933-020-01101-9.
Yang Y, Lu H, Qu J. Tendon pathology in hypercholesterolaemia patients: Epidemiology, pathogenesis and management.
J Orthop Translat. 2018;16:14-22. doi: 10.1016/j.jot.2018.07.003.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, et al. Bempedoic acid and cardiovascular outcomes
in statin-intolerant patients. N Eng J Med. 2023;388(15):1353-1364. doi: 10.1056/NEJMoa2215024.
Ballantyne CM, Banach M, Mancini GJ, Lepor NE, HanselmanJC, Zhao X, et al. Efficacy and safety of bempedoic
acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.
Atherosclerosis. 2018;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002.
Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ES, Ray KK. Long-term safety and efficacy of
bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia
(from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022;174:1-11. doi: 10.1016/j.amjcard.2022.03.020.
Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to
reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032. doi: 10.1056/NEJMoa1803917.
Laufs U, Banach M, Mancini GJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid
in patients with hypercholesterolemia and statin intolerance. J Am Heart Associat. 2019;8(7):e011662. doi: 10.1161/
JAHA.118.011662.
Goldberg AC, Leiter LA, Stroes ES, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo
added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular
disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780-1788. doi: 10.1001/jama.2019.16585.
Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of bempedoic acid among
patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes
Endocrinol. 2024;12(1):19-28. doi: 10.1016/S2213-8587(23)00316-9.
Leiter LA, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, et al. Bempedoic acid in patients with type 2
diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled
data from phase 3 clinical trials. Diabetes Obes Metab. 2022;24(5):868-880. doi: 10.1111/dom.14645.
Masson W, Lobo M, Lavalle-Cobo A, Masson G, Molinero G. Effect of bempedoic acid on new onset or worsening diabetes:
A meta-analysis. Diabetes Res Clin Pract. 2020;168:108369. doi: 10.1016/j.diabres.2020.108369.
Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U et al. Bempedoic acid safety analysis: Pooled data
from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649-659.e6. doi: 10.1016/j.jacl.2020.08.009.
Bays HE, Baum SJ, Brinton EA, Plutzky J, Hanselman JC, Teng R, et al. Effect of bempedoic acid plus ezetimibe
fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes
and hypercholesterolemia not treated with statins. Am J Prev Cardiol. 2021;4;8:100278. doi: 10.1016/j.ajpc.2021.100278.
Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic Acid for Primary Prevention of
Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023;330(2):131-140. doi: 10.1001/jama.2023.9696.
Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, et al. Association of Bempedoic Acid Administration
With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA
Cardiol. 2020;1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Н. С. Курочкина, М. Ю. Зубарева, Р. А. Артыкова, И. В. Сергиенко
This work is licensed under a Creative Commons Attribution 4.0 International License.
